Your Messages Inbox
Your Article Summary
See Latest ArticlesCopaxone Approved by the FDA for Patients with a First Clinical Event Suggestive of Multiple Sclerosis
Teva Pharmaceutical Industries, 03/05/09
Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for COPAXONE (glatiramer acetate injection) to include the treatment of patients who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with multiple sclerosis (MS).
Related Articles
Novartis receives approval in Switzerland for Celtura, a cell culture-based Influenza A(H1N1) pandemic vaccine
Novartis, 11/16/09
Relevance Score: 46%
FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09
Relevance Score: 46%
FDA Approves GARDASIL for Use in Boys and Young Men
Merck & Co., 10/19/09
Relevance Score: 46%
GSKs Cervarix becomes the first cervical cancer vaccine to gain approval in Japan
GlaxoSmithKline, 10/19/09
Relevance Score: 46%
Safer colchicine dosing regimen approved
American Pharmacists Association, 10/08/09
Relevance Score: 46%
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Bayer's Betaferon approved in China for Treatment of Multiple Sclerosis
BayNews International, 12/02/09
Article Search
Sponsor